Monograph
C01EB10 - Adenosine |
Not porphyrinogenic |
NP |
Rationale
Endogenous nucleoside. No relevant CYP metabolism.
Chemical description
Endogenous nucleoside.
Therapeutic characteristics
Used to stop paroxysmal supraventricular tachycardia.
Metabolism and pharmacokinetics
Adenosine is an endogenous nucleoside. Adenosine is rapidly taken up by most types of cells, including cellular elements of the blood (erythrocytes) and vascular endothelium, where it is rapidly degraded by deamination to inosine and subsequently to hypoxanthine. In addition, adenosine also undergoes phosphorylation to adenosine monophosphate (AMP) inside blood cells. Half time in blood less than 10 seconds. Non-CYP metabolism.
Published experience
Adenosine monophosphate has been proposed and used as a therapeutic agent in the acute porphyrias in the late 60s (Wiontzek, bibliographic data only + Oaks)
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Acute intermittent porphyria. Report of a case treated with adenosine 5 phosphoric acid. Dermatologica 1969; 138(1):10-18.
Oaks WW, Schultz J, Fleischmajer R. |
5764297 |
| 2. | [Treatment of acute intermittent prophyria using adenosine monophosphoric acid]. Med Klin 1969; 64(27):1238-1240.
Wiontzek H. |
5799781 |
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Finland© NAPOS 2024